The New England journal of medicineAgedFemaleHumansMaleMiddle Aged
Cardiovascular Outcomes with Tirzepatide versus Dulaglutide in Type 2 Diabetes.
Stephen J Nicholls, Imre Pavo, Deepak L Bhatt, John B Buse, Stefano Del Prato, Steven E Kahn, A Michael Lincoff, Darren K McGuire, Debra Miller, Michael A Nauck, Hiroshi Nishiyama, Steven E Nissen, Naveed Sattar, Govinda Weerakkody, Russell J Wiese
Published: 202510.1056/NEJMoa2505928
Abstract
BACKGROUND: Tirzepatide, a dual incretin agonist of the glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide receptors, has favorable effects on glycemic control and body weight. The effects on cardiovascular outcomes are uncertai…
Preview only. Read the full abstract at the source